Marine-Derived Compound Inhibits Breast Cancer in Preclinical Models
Researchers discover that cycloechinulin targets a specific signaling pathway to suppress tumor growth in patient-derived organoids.
Key takeaways
- Cycloechinulin is a novel diketopiperazine alkaloid isolated from the marine-derived fungus Aspergillus ochraceus.
- The compound significantly reduced breast cancer cell viability, restricted migration, and induced apoptosis in preclinical models.
- Cycloechinulin suppressed tumor growth and caused morphological degradation in multiple patient-derived breast cancer organoids.
- The treatment works by inhibiting the newly identified SGOL2/METTL3/ICAM2 signaling axis.
- Public database analysis linked high expression of the biomarker SGOL2 to advanced clinical stages and poor patient survival.
A compound derived from a marine fungus has demonstrated preclinical efficacy against breast cancer by disrupting a newly identified molecular pathway. The study, published in the journal Cellular signalling in September 2026, details how cycloechinulin—a novel diketopiperazine alkaloid isolated from the marine-derived fungus Aspergillus ochraceus—suppresses cancer progression in laboratory models.
Breast cancer remains a difficult malignancy to treat due to its high molecular heterogeneity and drug resistance. To address these therapeutic challenges, researchers evaluated the anti-cancer potential of cycloechinulin using in vitro breast cancer cell lines and validated the findings in patient-derived organoids, which are three-dimensional tissue cultures grown from patient cells.
The laboratory findings indicate that cycloechinulin significantly reduced breast cancer cell viability, suppressed DNA replication, restricted cell migration and invasion, and induced cellular apoptosis. Additionally, the compound led to robust growth inhibition and morphological degradation across multiple patient-derived breast cancer models, suggesting its potential as a novel chemical scaffold for targeted therapeutics.
What Happened
In the study, researchers used global transcriptional profiling via RNA sequencing to map the molecular changes caused by cycloechinulin. They identified Shugoshin 2 (SGOL2) as a key oncogenic biomarker. Analyzing public patient databases, the team verified that SGOL2 expression significantly correlates with advanced clinical stages and poor patient survival in breast cancer.
At the molecular level, treating breast cancer cells with cycloechinulin downregulated the protein expression of SGOL2 and its downstream effectors, METTL3 and ICAM2. To confirm the role of this pathway, the researchers performed a genetic knockdown of SGOL2. This knockdown reproduced the same anti-tumor effects observed with cycloechinulin treatment and suppressed both METTL3 and ICAM2 expression, confirming the importance of the SGOL2/METTL3/ICAM2 signaling axis.
What The Evidence Shows
The study published in Cellular signalling (September 2026) reports that cycloechinulin targets the SGOL2/METTL3/ICAM2 signaling axis. The evidence is derived from preclinical in vitro assays using breast cancer cell lines, patient-derived organoids, and RNA sequencing, along with bioinformatic validation using public patient databases. The exact sample size of the organoid models was not specified in the source.
What We Don't Know Yet
As a preclinical study, these findings are limited to laboratory cell lines and patient-derived organoids. The published source does not report human clinical data, toxicity profiles, or pharmacological behavior in living organisms. Furthermore, the source text does not specify the exact number of patient-derived organoids tested or the specific subtypes of breast cancer evaluated.
What Comes Next
The published source does not report specific next steps or plans for future clinical or animal trials. Unanswered questions include whether cycloechinulin can safely achieve therapeutic concentrations in living organisms and how it might perform in in vivo animal models before any potential human testing.
What This Means
The identification of the SGOL2/METTL3/ICAM2 signaling axis provides a new potential biomarker and therapeutic target for breast cancer. Cycloechinulin represents a promising natural lead compound and a novel chemical scaffold that could be used to develop targeted breast cancer treatments, though much more research is required before it can be evaluated in patients.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42697347/
Questions readers ask
- What is cycloechinulin and where does it come from?
- Cycloechinulin is a novel diketopiperazine alkaloid. It is isolated from a marine-derived fungus called Aspergillus ochraceus.
- How does cycloechinulin affect breast cancer cells in laboratory tests?
- In laboratory models, cycloechinulin reduced cell viability, suppressed DNA replication, restricted migration and invasion, and induced cellular apoptosis. It also caused growth inhibition and morphological degradation in patient-derived breast cancer organoids.
- What molecular pathway does this compound target?
- Cycloechinulin targets and inhibits a novel signaling pathway known as the SGOL2/METTL3/ICAM2 axis. It downregulates the protein expression of the biomarker SGOL2, along with its downstream effectors METTL3 and ICAM2.
- Has cycloechinulin been tested in human clinical trials?
- No, cycloechinulin has not been tested in human clinical trials. This research is currently in the preclinical stage, using cell lines and patient-derived organoid models in a laboratory setting.
What this means
The identification of the SGOL2/METTL3/ICAM2 signaling axis provides a new potential biomarker and therapeutic target for breast cancer. Cycloechinulin represents a promising natural lead compound and a novel chemical scaffold that could be used to develop targeted breast cancer treatments, though much more research is required before it can be evaluated in patients.
Limitations and uncertainties
- As a preclinical study, these findings are limited to laboratory cell lines and patient-derived organoids. The published source does not report human clinical data, toxicity profiles, or pharmacological behavior in living organisms. Furthermore, the source text does not specify the exact number of patient-derived organoids tested or the specific subtypes of breast cancer evaluated.
